DNA damage responses: Mechanisms and roles in human disease 2007 - G.H.A. Clowes Memorial Award lecture

Molecular Cancer Research

Volumn 6, Issue 4, 2008, Pages 517-524

  Kastan, Michael B ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; CHLOROQUINE; CYCLIN DEPENDENT KINASE INHIBITOR; CYTOTOXIC AGENT; NIBRIN; PROTEIN P53;

ARTICLE; ATAXIA TELANGIECTASIA; ATAXIA TELANGIECTASIA MUTATED GENE; ATHEROSCLEROSIS; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER SUSCEPTIBILITY; CELL STRESS; CHROMATIN IMMUNOPRECIPITATION; CHROMATIN STRUCTURE; DNA DAMAGE; DNA REPAIR; DOUBLE STRANDED DNA BREAK; ENZYME ACTIVITY; GENE; HUMAN; HUMAN GENOME; LOW DRUG DOSE; MAMMAL CELL; METABOLIC DISORDER; METABOLIC SYNDROME X; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN PHOSPHORYLATION;

AWARDS AND PRIZES; CELL CYCLE PROTEINS; DISEASE; DNA DAMAGE; DNA-BINDING PROTEINS; HUMANS; PROTEIN-SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

ATAXIA TELANGIECTASIA; MAMMALIA;

EID: 42049089502     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-08-0020     Document Type: Article

References (39)

1. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991;51:6304-11.
2. Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci U S A 1992;89:7491-5.
3. Kastan MB, Zhan Q, El-Deiry WS, et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 1992;71:587-97.
4. El-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-25.
5. 1 cyclin-dependent kinases. Cell 1993;75:805-16.
6. Siliciano JD, Canman CE, Taya Y, Sakaguchi K, Appella E, Kastan MB. DNA damage induces phosphorylation of the amino terminus of p53. Genes Dev 1997;11:3471-81.
7. Savitsky K, Bar-Shira A, Gilad S, et al. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science 1995;268:1749-53.
8. Canman CE, Lim D-S, Cimprich KA, et al. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science 1998;281:1677-9.
9. Banin S, Moyal L, Shieh S-Y, et al. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 1998;281:1674-7.
10. Kim S-T, Lim D-S, Canman CE, Kastan MB. Substrate specificities and identification of putative substrates of ATM kinase family members. J Biol Chem 1999;274:37538-43.
11. Kastan MB, Bartek J. Cell-cycle checkpoints and cancer. Nature 2004;432:316-23.
12. Bakkenist CJ, Kastan MB. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 2003;421:499-506.
13. Lee JH, Xu B, Lee CH, et al. Distinct functions of Nijmegen breakage syndrome in ataxia telangiectasia mutated-dependent responses to DNA damage. Mol Cancer Res 2003;1:674-81.
14. Falck J, Coates J, Jackson SP. Conserved modes of recruitment of ATM, ATR and DNA-PKcs to sites of DNA damage. Nature 2005;434:605-11.
15. Kitagawa R, Bakkenist CJ, McKinnon PJ, Kastan MB. Phosphorylation of SMC1 is a critical downstream event in the ATM-NBS1-BRCA1 pathway. Genes Dev 2004;18:1423-38.
16. Kozlov SV, Graham ME, Peng C, Chen P, Robinson PJ, Lavin MF. Involvement of novel autophosphorylation sites in ATM activation. EMBO J 2006;25:3504-14.
17. Uziel T, Lerenthal Y, Moyal L, Andegeko Y, Mittelman L, Shiloh Y. Requirement of the MRN complex for ATM activation by DNA damage. EMBO J 2003;22:5612-21.
18. 2/M checkpoint. EMBO J 2003;22:6610-20.
19. You Z, Chahwan C, Bailis J, Hunter T, Russell P. ATM activation and its recruitment to damaged DNA require binding to the C terminus of Nbs1. Mol Cell Biol 2005;25:5363-79.
20. Lee JH, Paull TT. Direct activation of the ATM protein kinase by the Mre11/Rad50/Nbs1 complex. Science 2004;304:93-6.
21. Lee JH, Paull TT. ATM activation by DNA double-strand breaks through the Mre11-Rad50-Nbs1 complex. Science 2005;308:551-4.
22. Dupre A, Boyer-Chatenet L, Gautier J. Two-step activation of ATM by DNA and the Mre11-Rad50-Nbs1 complex. Nat Struct Mol Biol 2006;13:451-7.
23. Pellegrini M, Celeste A, Difilippantonio S, et al. Autophosphorylation at serine 1987 is dispensable for murine Atm activation in vivo. Nature 2006;443:222-5.
24. Berkovich E, Monnat RJ Jr., Kastan MB. Roles of ATM and NBS1 in chromatin structure modulation and DNA double-strand break repair. Nat Cell Biol 2007;9:683-90.
25. Smerdon MJ, Lieberman MW. Nucleosome rearrangement in human chromatin during UV-induced DNA repair synthesis. Proc Natl Acad Sci U S A 1978;75:4238-41.
26. Tsukuda T, Fleming AB, Nickoloff JA, Osley MA. Chromatin remodelling at a DNA double-strand break site in Saccharomyces cerevisiae. Nature 2005;438:379-83.
27. Pandita TK, Hittelman WN. The contribution of DNA and chromosome repair deficiencies to the radiosensitivity of ataxia-telangiectasia. Radiat Res 1992;131:214-23.
28. Pandita TK, Hittelman WN. Initial chromosome damage but not DNA damage is greater in ataxia telangiectasia cells. Radiat Res 1992;130:94-103.
29. Morgan SE, Lovly C, Pandita TK, Shiloh Y, Kastan MB. Fragments of ATM which have dominant-negative or complementing activity. Mol Cell Biol 1997;17:2020-39.
30. Shroff R, Arbel-Eden A, Pilch D, et al. Distribution and dynamics of chromatin modification induced by a defined DNA double-strand break. Curr Biol 2004;14:1703-11.
31. Gorgoulis VG, Vassiliou LV, Karakaidos P, et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005;434:907-13.
32. Bartkova J, Rezaei N, Liontos M, et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 2006;444:633-7.
33. MacLean KH, Dorsey FC, Cleveland JL, Kastan MB. Targeting lysosomal degradation induces p53-dependent cell death and prevents cancer in mouse models of lymphomagenesis. J Clin Invest 2007;118:79-88.
34. Loehberg CR, Thompson T, Kastan MB, et al. Ataxia telangiectasia-mutated and p53 are potential mediators of chloroquine-induced resistance to mammary carcinogenesis. Cancer Res 2007;67:12026-33.
35. Yang D, Kastan MB. Participation of ATM in insulin signalling through phosphorylation of eIF-4E binding protein 1 (4E-BP1). Nat Cell Biol 2000;2:893-8.
36. Schalch DS, McFarlin DE, Barlow MH. An unusual form of diabetes mellitus in ataxia telangiectasia. N Engl J Med 1970;282:1396-402.
37. Bar RS, Levis WR, Rechler MM, et al. Extreme insulin resistance in ataxia telangiectasia. N Engl J Med 1978;298:1164-71.
38. Su Y, Swift M. Mortality rates among carriers of ataxia-telangiectasia mutant alleles. Ann Intern Med 2000;133:770-8.
39. Schneider JG, Finck BN, Ren J, et al. ATM-dependent suppression of stress signaling reduces vascular disease in metabolic syndrome. Cell Metab 2006;4:377-89.